FSA
RGNX icon

Fort Sheridan Advisors’s Regenxbio RGNX Stock Holding History

Fort Sheridan Advisors’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-5,253
Closed -$220K – 208
2021
Q3 		$220K Hold
5,253
– – 0.07% 165
2021
Q2 		$204K Buy
+5,253
New +$188K 0.07% 167

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fort Sheridan Advisors's RGNX Position: Q4 2021 in Review

Fort Sheridan Advisors sold out of Regenxbio (RGNX) in Q4 2021, closing a stake of 5,253 shares — an estimated $220K sold.

Fort Sheridan Advisors first reported a position in RGNX in Q2 2021 and held it in 2 quarters. The position peaked at $220K in Q3 2021. 172 funds tracked by Wall St. Rank hold RGNX as of Q4 2021.

  • Fort Sheridan Advisors reported no remaining Regenxbio position as of Q4 2021 after selling out during the quarter.
  • Fort Sheridan Advisors sold 5,253 Regenxbio shares in Q4 2021, an estimated $220K.
  • Fort Sheridan Advisors first reported a position in Regenxbio in Q2 2021 and held it in 2 quarters.
  • Fort Sheridan Advisors's Regenxbio position peaked at $220K in Q3 2021.
  • 172 funds tracked by Wall St. Rank held Regenxbio as of Q4 2021.

Based on Fort Sheridan Advisors's 13F filing for Q4 2021, filed 10 Feb 2022.